GM's Weapons Pact Adds a New Arrow to Its Quiver, but Core Risks Remain

What happened

GM is collaborating with Lockheed Martin to leverage its manufacturing capacity for weapons production, as reported by The Wall Street Journal. This diversification move comes as GM has been grappling with multi-billion-dollar writedowns in its EV and China operations, and a stock that has surged ~59% in the past year to ~$85. The partnership could open a new, potentially high-margin revenue stream, but near-term financial impact is likely negligible given the early stage. Meanwhile, the core investment thesis remains fraught: GM's North American truck/SUV profits, while strong, face policy and competitive pressures, and the company's EV and China charges continue to accumulate. At ~27x trailing EPS, the stock prices in flawless execution, leaving little room for error from either its traditional business or these nascent ventures.

Implication

While GM's foray into defense manufacturing may eventually diversify earnings and provide a hedge against automotive cyclicality, it does not address the immediate structural challenges highlighted in the DeepValue analysis: thin GMNA margins, recurring EV/China impairments, and a stretched valuation at ~27x earnings. The partnership is likely to be a multi-year, low-revenue contributor initially, and investors should not extrapolate a quick fix. The stock has already priced in a rosy scenario, and any disappointment in core auto earnings or further impairments could lead to multiple compression. We see this news as a modest positive that may support sentiment, but it does not alter our bearish stance given the margin of safety remains insufficient. Wait for a better entry point or clearer evidence of margin stabilization before considering an upgrade.

Thesis delta

The weapons collaboration introduces a potential long-term revenue source but does not fundamentally change the near- to medium-term outlook. The thesis remains that GM's valuation embeds overly optimistic assumptions about stable ICE profits and contained restructuring costs. This news provides a slight upside optionality but does not reduce the risk of an earnings miss or additional writedowns. We maintain our POTENTIAL SELL rating and see no reason to adjust our target entry of $65.